|March 18, 2003
|REBROADCAST OF HEMISPHERX'S MARCH 18, 2003 CONFERENCE CALL AVAILABLE ON COMPANY'S WEBSITE OR VIA TELEPHONE REPLAY
|Philadelphia, PA, Tuesday, March 18, 2003: Hemispherx Biopharma Inc. (AMEX: HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome, today hosted a conference call in which it discussed its recent acquisition of certain assets from Interferon Sciences, Inc. (IFSC), a biotechnology company, including the rights to its patented drug, the Alferon N Injection®, approved by the FDA for venereal warts and currently the only FDA approved natural interferon therapy.
During the call, the Company discussed the acquisition, the accompanying $5,425,000 financing the Company completed and the forward strategies for the commercialization of the Company’s pharmaceutical pipeline.
In order to listen to the rebroadcast, which will be available until April 1, 2003, please go to www.Hemispherx.net and follow the link, or dial (800) 428 – 6051 or (973) 709 – 2089 for the telephone replay and state the password, which is 287828.
Hemispherx Biopharma, Inc is a biopharmaceutical company that focuses on the innovative development of ribonucleic acid (RNA) drug technologies intended to enhance the natural anti-viral defense system of the human body, representing a potential new class of pharmaceutical products. Its primary product, Ampligen, is in two phase IIb clinical trials for HIV/AIDS, one experimental Salvage Therapy and one Strategic Treatment Intervention (STI), and a phase III clinical trial for Chronic Fatigue Syndrome (CFS). For more information, you can visit the corporate website at www.Hemispherx.net.
Hemispherx Biopharma, Inc., Investor Relations
(215) 988-1712, Fax: (215) 988-1554
Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6223
Robert Giordano, MRB Investor Relations
(212) 495-0200, Fax: (212) 495-0746
HEB's Web Site: www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results including financial results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company’s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.